13F Holdings
中文EN

SIGA SIGA TECHNOLOGIES INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1010086 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-69.6%
TTM net income YoY-99.1%
TTM EPS YoY-99.0%
Revenue 3-yr CAGR14.6%
Net income 3-yr CAGR—

Margins

Gross margin54.0%
Operating margin-14.2%
Net margin1.3%
FCF margin-22.1%
EBITDA margin-13.0%

Returns

ROE0.4%
ROA0.3%
ROIC (approx.)-15.0%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets5.4%
Debt / equity0.00x
Current ratio24.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-16.81x
Accruals ratio6.0%
Payout ratio6,325.2%
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$94.57M$138.72M$139.92M$110.78M$133.67M
Cost of revenue$29.70M$31.29M$17.83M$10.43M$16.60M
Gross profit$64.87M$107.43M$122.09M$100.34M$117.07M
R&D expense$19.96M$12.31M$16.43M$22.53M$9.94M
SG&A expense$21.21M$25.14M$22.04M$35.12M$18.03M
Operating income$23.70M$69.98M$83.62M$42.70M$89.09M
Interest expense———$0$0
Pretax income$30.38M$76.07M$87.78M$44.13M$89.31M
Income tax$7.10M$16.86M$19.71M$10.23M$19.86M
Net income$23.28M$59.21M$68.07M$33.90M$69.45M
EBITDA$24.26M$70.52M$84.16M$43.22M$89.62M
EPS (basic)0.330.830.950.460.92
EPS (diluted)0.320.820.950.460.91
Dividends declared per share0.600.600.450.45—
Weighted avg. shares (diluted)71.87M71.91M71.68M73.55M76.40M
Balance sheet
Cash & equivalents$154.97M$155.40M$150.15M$98.79M$103.14M
Receivables$3.26M$21.17M$21.13M$45.41M$83.65M
Inventory$49.05M$49.56M$64.22M$39.27M$19.51M
Current assets$212.86M$231.04M$238.99M$185.79M$208.75M
PP&E, net$1.09M$1.30M$1.33M$1.85M$2.37M
Goodwill$898,334$898,334$898,334$898,334$898,334
Total assets$219.47M$244.34M$254.35M$195.04M$214.73M
Current liabilities$17.99M$25.33M$54.12M$21.52M$30.49M
Total liabilities$20.65M$28.53M$57.49M$24.88M$40.41M
Shareholders' equity$198.82M$215.80M$196.86M$170.16M$174.31M
Shares outstanding71.61M71.40M71.09M72.68M73.54M
Cash flow statement
Operating cash flow$43.47M$48.76M$94.80M$41.61M$11.49M
Capital expenditure$355,009$42,450$21,686$0$50,620
Free cash flow$43.12M$48.72M$94.78M$41.61M$11.44M
Investing cash flow-$355,009-$42,450-$21,686$0-$50,620
Financing cash flow-$43.55M-$43.46M-$43.42M-$45.96M-$26.20M
Depreciation & amortization$562,607$538,421$538,293$517,643$522,368
Stock-based compensation$3.68M$3.64M$2.05M$1.78M$1.27M
Dividends paid$43.12M$42.67M$32.14M$32.94M$0
Share buybacks$0$0$11.07M$13.01M$26.02M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.